Sanovas, Inc. Launches Sinus Endoscopy Business to Address Global Demand For Office Based Treatments of Chronic Sinusitis

SAUSALITO, Calif., Dec. 1, 2016 /PRNewswire/ -- Sanovas, Inc., a life science asset holding company and medical technology accelerator, announced today the launch of its wholly-owned subsidiary, SinuGeniX, Inc. and its RegENT™ Sinus Treatment System.

Logo - http://photos.prnewswire.com/prnh/20161130/444495LOGO 

Sinusitis is one of the most prevalent of human diseases, second only to periodontal disease. Both conditions involve biofilm infections and undesirable host inflammatory responses. According to the Centers of Disease Control and Prevention (CDC), in the U.S., about 12.1% of the adult population or 28.5 Million people are suffering from chronic sinusitis, making it more prevailing than diabetes and asthma.

Chronic sinusitis patients are typically first treated with medications such as nasal steroids, decongestants, antihistamines, saline solutions and antibiotics. Although treatment with these medications is often successful, patients can experience side effects with long term use.

"Peer reviewed data suggests that more than 20% of the 13 million U.S. patients that are treated with medication for chronic sinusitis fail to respond.  So, there are about 2.6 million patients looking to surgery as an ultimate solution," said Dr. Chris Baker, SinuGeniX's Chief Medical Officer and a Co-Inventor of the RegENT Sinus Treatment System. "However, current treatments in sinus surgery aren't precise and come with complications."

The high prevalence of chronic sinusitis has been driving the demand for ENT treatments such as endoscopic sinus surgeries, functional endoscopic sinus surgery (FESS), and balloon sinus dilatation. Thus, the growing prevalence of sinusitis is expected to propel the growth of the ENT devices market.

"Traditional Functional Endoscopic Sinus Surgery (FESS) and, alternatively current balloon dilatation methods can 'over-fracture' the bony ostia as they open the sinus. Fractured ostia can lead to scarring, inflammation, recurrent sinusitis, and revision procedures.  Sometimes, removal of vital anatomy can lead to aesthetic problems," related Dr. Baker.

"SinuGeniX's RegENT Sinus Treatment System is a first-to-market suite of integrated tools intended to facilitate office-based treatment solutions that are safe and cost-effective," said Larry Gerrans, Sanovas' and SinuGenix's Founder and the Co-Inventor of the RegENT STS.  "The system was designed to provide surgical precision sufficient to preserve vital anatomy, improve outcomes and achieve lasting relief for patients. Most importantly, the RegENT System was developed to serve both the domestic and emerging global markets with a vertically integrated suite of 'Smart' tools that are affordable and portable."

According to Markets and Markets Research, "Chronic sinusitis is one of the top 10 medical conditions and contributes around $8.6 Billion of direct healthcare costs in the U.S. The global ENT devices market is expected to reach $14.1 Billion by 2020 from $9.595 Billion in 2015, at a CAGR of 6.5% during the forecast period. Growth in the ENT Devices market is mainly driven by the high prevalence of chronic sinusitis, rising geriatric population, favorable reimbursement scenarios for ENT procedures in developed countries, rising adoption of minimally invasive ENT procedures, increasing presence of prominent players in the ENT devices market, and technological advancements."

The RegENT™ Sinus Treatment System (STS) is intended to advance the art of sinus surgery by providing faster access with controlled, regional anesthetization and drug delivery. The system offers swift, agile guide-sheath navigation with direct visualization and a semi-compliant, smart balloon catheter that acquires physiologic feedback of the anatomy to inform the system in gently dilating the sinuses without fracturing the bony ostia that make up the sinus passageways; leaving essential anatomy intact.

RegENT STS will offer doctors a better solution for their patients care and eliminate the time, cost and inconvenience of pre-surgical set-up and post-surgical recovery.

SinuGeniX, Inc. is a subsidiary of Sanovas, Inc.

Contact:
Steve Goldsmith
SinuGeniX, Inc. 
415-729-9391 x1023
[email protected]

SOURCE Sanovas, Inc.

Related Links

http://www.sanovas.com